SYN Synthetic Biologics Inc.

0.55
+0.04  (+8%)
Previous Close 0.51
Open 0.54
Price To Book 54.9
Market Cap 9,226,730
Shares 16,806,430
Volume 1,004,889
Short Ratio 0.14
Av. Daily Volume 192,475
Stock charts supplied by TradingView

NewsSee all news

  1. Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

    ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  2. Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

    ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  3. Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

    ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  4. Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

    ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  5. Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

    ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 1H 2020.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 3 trial being considered.
SYN-004 (ribaxamase)
C. difficile Infection
Phase 1b/2 trial to commence enrolment 1Q 2020.
SYN-004
Allogeneic hematopoietic cell transplantation (HCT)

Latest News

  1. Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

    ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  2. Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

    ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  3. Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

    ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  4. Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

    ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

  5. Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

    ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients,